中国P站

Innate Lymphoid Cells; Mucosal Immunity; Cytokines; Inflammation; IL-22; IL-17; ILC2; ILC3; Inflammatory Bowel Disease; Asthma

Introduction

Innate Lymphoid Cells (ILCs) play a vital role in maintaining mucosal homeostasis and orchestrating inflammatory responses[1].

Cytokine networks, especially those involving IL-22 and IL-17, are central to ILC function and their interactions with other immune cells[1].

Dysregulation of these networks can lead to chronic inflammatory diseases[1].

The interplay between epithelial cells and ILCs at mucosal surfaces is crucial for barrier function and immune defense[2].

Epithelial-derived cytokines, such as TSLP and IL-25, activate ILC2s, leading to the production of IL-5 and IL-13, which contribute to type 2 immunity and tissue repair[2].

ILC3s are essential for intestinal immunity by producing IL-22, which promotes epithelial cell proliferation, antimicrobial peptide production, and barrier integrity[3].

The transcription factor RORγt is a master regulator of ILC3 development and function[3].

The role of ILCs in Inflammatory Bowel Disease (IBD) is complex, with different ILC subsets contributing to both protective and pathogenic responses[4].

IL-17-producing ILCs can exacerbate intestinal inflammation, while IL-22-producing ILCs can promote tissue repair[4].

Type 2 inflammation at mucosal sites is often driven by ILC2s, which are activated by epithelial-derived alarmins and produce IL-5 and IL-13[5].

These cytokines contribute to eosinophil recruitment, mucus production, and tissue remodeling in allergic diseases[5].

The development and function of ILCs are influenced by the gut microbiota[6].

Microbial metabolites, such as short-chain fatty acids, can modulate ILC activity and cytokine production, contributing to mucosal homeostasis[6].

The cytokine IL-33 plays a critical role in promoting ILC2-mediated inflammation in the lungs during asthma[7].

Blocking IL-33 signaling can reduce airway inflammation and hyperreactivity[7].

The interaction between ILCs and macrophages is important for regulating inflammation and tissue repair[8].

Macrophages can produce cytokines that influence ILC function, and ILCs can modulate macrophage polarization[8].

ILC subsets exhibit plasticity, meaning they can change their phenotype and function in response to environmental cues[9].

This plasticity allows ILCs to adapt to different inflammatory conditions and contribute to both protective and pathogenic responses[9].

Targeting ILCs and their associated cytokine networks represents a promising therapeutic strategy for treating chronic inflammatory diseases of the mucosa, such as IBD and asthma[10].

Selective inhibitors of ILC activation or cytokine production are under development[10].

Description

Innate Lymphoid Cells (ILCs) are crucial for maintaining mucosal homeostasis and orchestrating inflammatory responses. Cytokine networks, particularly those involving IL-22 and IL-17, play a central role in ILC function and interactions with other immune cells[1]. Dysregulation of these networks can contribute to chronic inflammatory diseases[1]. The interplay between epithelial cells and ILCs at mucosal surfaces is critical for barrier function and immune defense[2]. Epithelial-derived cytokines, such as TSLP and IL-25, activate ILC2s, leading to the production of IL-5 and IL-13, which contribute to type 2 immunity and tissue repair[2].

ILC3s are essential for intestinal immunity as they produce IL-22, promoting epithelial cell proliferation, antimicrobial peptide production, and barrier integrity[3]. The transcription factor RORγt is a key regulator of ILC3 development and function[3]. The role of ILCs in Inflammatory Bowel Disease (IBD) is intricate, with different ILC subsets involved in both protective and pathogenic mechanisms[4]. IL-17-producing ILCs can exacerbate intestinal inflammation, while IL-22-producing ILCs can aid in tissue repair[4].

Type 2 inflammation at mucosal sites is often driven by ILC2s, which are activated by epithelial-derived alarmins and produce IL-5 and IL-13[5]. These cytokines contribute to eosinophil recruitment, mucus production, and tissue remodeling in allergic diseases[5]. The development and function of ILCs are influenced by the gut microbiota[6]. Microbial metabolites, such as short-chain fatty acids, can modulate ILC activity and cytokine production, supporting mucosal homeostasis[6].

ILC subsets display plasticity, enabling them to change their phenotype and function in response to environmental signals[9]. This adaptability allows ILCs to respond to various inflammatory conditions, contributing to both protective and pathogenic reactions[9]. Targeting ILCs and their cytokine networks offers a promising therapeutic approach for treating chronic inflammatory mucosal diseases, such as IBD and asthma[10]. Selective inhibitors of ILC activation or cytokine production are being developed as potential treatments[10]. The interaction between ILCs and macrophages is vital for regulating inflammation and tissue repair[8]. Macrophages can produce cytokines that affect ILC function, and ILCs can modulate macrophage polarization[8].

Conclusion

Innate Lymphoid Cells (ILCs) are vital for maintaining mucosal homeostasis and regulating inflammatory responses. Cytokine networks, specifically those involving IL-22 and IL-17, are central to ILC function and their interactions with other immune cells; dysregulation of these networks can lead to chronic inflammatory diseases. Epithelial cells and ILCs interplay at mucosal surfaces is critical for barrier function and immune defense, with epithelial-derived cytokines activating ILC2s to produce IL-5 and IL-13, contributing to type 2 immunity and tissue repair. ILC3s are essential for intestinal immunity through IL-22 production, which promotes epithelial cell proliferation, antimicrobial peptide production, and barrier integrity; the transcription factor RORγt is a key regulator of ILC3 development and function. The role of ILCs in Inflammatory Bowel Disease (IBD) is complex, with different ILC subsets contributing to both protective and pathogenic responses; IL-17-producing ILCs can worsen intestinal inflammation, while IL-22-producing ILCs can promote tissue repair. ILC2s often drive type 2 inflammation at mucosal sites, activated by epithelial-derived alarmins and producing IL-5 and IL-13, contributing to eosinophil recruitment, mucus production, and tissue remodeling in allergic diseases. The gut microbiota influences ILC development and function; microbial metabolites, such as short-chain fatty acids, can modulate ILC activity and cytokine production, maintaining mucosal homeostasis. ILC subsets exhibit plasticity, changing their phenotype and function in response to environmental cues, allowing them to adapt to different inflammatory conditions. Targeting ILCs and their cytokine networks is a promising therapeutic strategy for chronic inflammatory diseases of the mucosa, such as IBD and asthma, with selective inhibitors under development.

References

1. Shinya S, Mathias L, Katarzyna S (2019) .Nat Immunol 20:1125-1135.

   , ,

2. Tomoya N, Keisuke T, Shinji T (2020) .Allergy 75:2348-2358.

   , ,

3. Eva AK, Michael AK, Gunnar W (2019) .Nat Immunol 20:1447-1457.

   , ,

4. Laura AM, Julia V, Birte S (2021) .Gut 70:2086-2097.

   , ,

5. Shigeo K, Kazuyo M, Masaru T (2020) .Nat Immunol 21:1169-1178.

   , ,

6. Min-Hee K, Nahyun K, Yuree K (2021) .Mucosal Immunol 14:1103-1115.

   , ,

7. Tarik YH, Nicola EH, Helen EJ (2018) .J Exp Med 215:57-64.

   , ,

8. Noriko S, Christian AV, Isabelle L (2019) .Immunity 34:587-595.

   , ,

9. Gerard E, James PDS, Eric V (2015) .Nat Immunol 16:1107-1115.

   , ,

10. Yannick S, Melanie F, Catherine BL (2017) .Nat Immunol 18:333-340.

    , ,